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ABSTRACT: The miniaturization, sophistication, pro-
liferation, and accessibility of technologies are enabling
the capture of more and previously inaccessible phe-
nomena in Parkinson’s disease (PD). However, more
information has not translated into a greater under-
standing of disease complexity to satisfy diagnostic
and therapeutic needs. Challenges include noncompati-
ble technology platforms, the need for wide-scale and
long-term deployment of sensor technology (among vul-
nerable elderly patients in particular), and the gap
between the “big data” acquired with sensitive mea-
surement technologies and their limited clinical applica-
tion. Major opportunities could be realized if new
technologies are developed as part of open-source
and/or open-hardware platforms that enable multichan-
nel data capture sensitive to the broad range of motor
and nonmotor problems that characterize PD and are
adaptable into self-adjusting, individualized treatment
delivery systems. The International Parkinson and
Movement Disorders Society Task Force on Technology
is entrusted to convene engineers, clinicians, research-
ers, and patients to promote the development of inte-
grated measurement and closed-loop therapeutic
systems with high patient adherence that also serve to
(1) encourage the adoption of clinico-pathophysiologic
phenotyping and early detection of critical disease mile-
stones, (2) enhance the tailoring of symptomatic ther-
apy, (3) improve subgroup targeting of patients for
future testing of disease-modifying treatments, and (4)
identify objective biomarkers to improve the longitudinal
tracking of impairments in clinical care and research.
This article summarizes the work carried out by the
task force toward identifying challenges and opportuni-
ties in the development of technologies with potential
for improving the clinical management and the quality
of life of individuals with PD. VC 2016 International Par-
kinson and Movement Disorder Society
Key Words: digital health; digital biomarkers;
eHealth; Parkinson’s disease; precision medicine;
remote monitoring; technology; wearable technology
During the past decade, a multitude of technology-
based objective measures (TOMs) of parkinsonian
impairments have been developed, bringing with them
the promise of substantially changing the diagnostic,
monitoring, and therapeutic landscape in Parkinson’s
disease (PD). Sensors, mobile communications, cloud
computing, advanced analytics, and the Internet of
Things (wireless connectivity of all electronic
devices)1,2 are among the innovations that have the
potential to transform healthcare and our approach to
patients with chronic, complex, and fluctuating disor-
ders. With the abundance of new technologies, their
growing power and versatility, and the smart algo-
rithms on which they increasingly rely, our field needs
to ponder the basic questions of why we should even
consider adding alternative measures; what clinical
needs should be addressed; what instruments should
be used; how to deploy new technologies with mini-
mal burden, disruption, and cost and maximal compli-
ance; and whether they replace or complement
existing resources. Unfortunately, technology develop-
ers appear to be operating in competing “islands of
expertise” whose focus may be redundant, thus
increasing the risk of duplicating rather than extend-
ing progress while potentially making their technolo-
gies incompatible with those of other developers. Also,
not all technologies are primarily driven by burning
questions from within the clinical field, sometimes cre-
ating technical solutions that—clever as they may be—
remain in search of a clinical indication.
In the absence of well-established and validated bio-
markers of diagnosis or disease progression, PD
remains a clinically defined disease. Today, clinical
scales and traditional patient-reported outcomes con-
tinue to be the primary assessment tools or endpoints
in PD clinical care and research. However, there is a
growing awareness that TOMs may improve the sensi-
tivity, accuracy, reproducibility, and feasibility of
objectively capturing the full complexity and diversity
of changes in motor and nonmotor behaviors.3-7
Examples include the difficulty to reliably evaluate
fluctuating events (eg, the variable response to
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medication), to capture rare incidents (eg, falls or
freezing of gait), or to assess behaviors that, by defini-
tion, take place over long periods of time outside the
clinical examination room (eg, physical activities in
everyday life). The ability to remotely capture behav-
ioral data and use it to optimize treatment strategies
has the potential to finally “close the loop” and
address critical knowledge gaps.8 Despite multiple
ongoing projects by stakeholders in academia and
industry, it remains challenging to determine what ini-
tiatives have the capacity to be scaled up, and what
type of deployment would ensure the highest yield in
the future.
This review summarizes the deliberations of the
International Parkinson and Movement Disorders
Society Task Force on Technology. As a first step, we
concentrated on assessing the landscape of wearable
devices and other technologies for individualized
assessments as well as the therapeutic and scientific
uncertainties they stand to fill rather than on the clini-
metric properties of any of the growing list of mea-
surement technologies that have become available in
the past 10 years. For the latter purpose, a number of
reviews have been recently published.9-11 The task
force is entrusted with bringing together experts from
the device and biopharmaceutical industry, clinicians,
researchers, engineers, and patients to brainstorm on
needed developments to advance PD research and
care. We aim to appraise the extent to which technol-
ogy and data analysis in general, and TOMs in partic-
ular, can bring robust granularity to the clinical
complexity of PD to facilitate clinico-pathophysiologic
phenotyping, the detection of prodromal symptoms,
the improvement of diagnostic accuracy, and progres-
sion monitoring and to begin the process of integrat-
ing technology-based diagnostics and actionable
pharmacological and nonpharmacological therapeutics
for clinical applications.
Definitions and Objectives
TOMs are the outcomes of device-based instru-
mented clinical tests conducted by clinicians in stand-
ardized environments to objectively measure specific
behaviors or self-administered by patients to detect
and monitor impairments in specific or overall func-
tion in everyday life. Initially, TOMs targeted motor
phenomena, such as gait or balance, and were gath-
ered in specialized movement laboratories.12 More
recently they have been extended to devices worn by
the patient (ie, wearable sensors and systems) in the
clinic and—for remote monitoring—in the home or
community settings (Fig. 1).13-15 The goal of wearable
technologies is to maximize the “ecological” validity
as well as the temporal and spatial resolution of cap-
turing motor and nonmotor phenomena that are natu-
rally expected to change over time. As such, wearable
technology may provide a more realistic portrayal of
behaviors of interest in clinical and research settings.16
In addition, in the research arena, increasing the tem-
poral and spatial resolution of a targeted behavior is
expected to reduce the sample size required to evalu-
ate the effect of therapeutic interventions.17
Important goals of TOMs are to provide objective
parameters in the detection and monitoring of motor
and nonmotor functions, thereby enhancing the qual-
ity of treatment delivery and allowing for personalized
care (Table 1). Currently available wearable technolo-
gies (such as inertial sensors and surface electromyog-
raphy [EMG]) are—with variable success—capable of
capturing the number and intensity of multiple activ-
ities, such as the frequency and amplitude of move-
ments during the day and while asleep, the frequency
with which tremor and dyskinesia appear and disap-
pear during the day, and the fluctuations in the sever-
ity of gait and balance impairments.18-22 The use of
consumer wearable technologies in medicine is becom-
ing increasingly more common. For instance, in the
field of sleep medicine, the use of actigraphy for sleep
monitoring may be used to supplant more traditional
methods such as polysomnography because of its
validity, lower cost, and ability to evaluate individuals
in their homes during a longer period of time.23
Advanced wearable technologies can also precisely
monitor skin conductance, respiratory rate, blood
pressure, and oximetry and provide surface EMG,
electrocardiography, and electroencephalography trac-
ings.24-29 Furthermore, the ability to collect TOMs
using smart devices (mobile phones, tablets, and smart
watches) provides additional opportunities to collect
and analyze numerous clinically relevant parameters
(eg, posture, balance, dexterity, voice and speech pat-
terns, facial expression, eye tracking, medication, and
exercise compliance and adherence) and develop com-
munication portals to improve patient engagement
and self-management.
Caveat Emptor: Why Measure at All?
The often-implied assumption that the sole existence
of a PD symptom justifies its measurement and that
all PD-related phenomena should be measured must
be dispelled. A measure is justified if it enhances our
understanding of a complex disease or aids in testing
or delivering a therapy. The use of measurements to
improve therapy is filled with rich examples from
other branches of medicine (eg, glucose monitoring for
insulin pumps, cardiac defibrillators). It should be
remembered that every qualitative clinical assessment
is a form of measurement and that the use of quantita-
tive measures carries the potential for improving the
decision-making process as to the need and dose of
therapy. Implicit however is that what is being
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TABLE 1. Examples of available and needed technologies relevant to the diagnosis and clinical management of patients
with Parkinson’s disease
Clinical problem Available/needed technologies Clinical objective
Improving diagnosis Needed: sensors for prodromal features (e.g., constipation,
REM sleep behavior, anosmia); blood sensors for
biomarkers (a-synuclein, proteinomics, etc.)
Enable population screening for PD, including
the earliest possible (prodromal) stages
Monitoring response to therapy
and motor complications
(motor fluctuations, dyskinesia)
Available: accelerometers, gyroscopes, magnetometers,
electrogoniometers, surface EMG sensors
Needed: small patches onto the skin or other sensors
that improve patient adherence
Collect ecologically valid data of motor fluctuations,
falls, freezing of gait episodes
Implement sensor-based closed-loop technologies
capable of delivering treatments (eg, infusion pump)
Monitoring nonmotor symptoms
and progression
Available (but requiring improvements): sweat sensors,
skin conductance sensors, heart rate sensors,
blood pressure sensors
Collect ecologically valid data of nonmotor
symptoms and progression
Improving medical treatment Available (but requiring improvements): oral capsules,
subcutaneous and gastrointestinal infusion pumps
Implement adjustable extended-release drug
formulations, smart (self-adjusting) levodopa
delivery infusion systems
Enhancing surgical treatment Available (but requiring improvements): STN DBS,
GPi DBS, Vim thalamus DBS
Implement closed-loop STN and GPi DBS
(variable stimulation based on local
field potentials)
Improving rehabilitation interventions Available: accelerometers, gyroscopes, magnetometers,
electrogoniometers, surface EMG sensors,
pulse oximetry sensors, respiratory rate sensors,
blood pressure sensors
Implement closed-loop cueing and feedback
systems validated for home use
DBS, deep brain stimulation; EMG, electromyography; GPi, globus pallidus pars interna; PD, Parkinson’s disease; REM, rapid eye movement; STN, subthala-
mic nucleus; Vim, ventrointermedial nucleus.
FIG. 1. Schematic representation of a subject undergoing monitoring in the home setting using wearable and ambient sensors. The technology
shown includes a wireless unit strapped around the wrist, Band-Aid-like sensors attached to the lower limbs, a wearable camera worn as a pend-
ant, a smart watch, and a mobile phone clipped on the belt used as gateway to relay the data to the cloud to assess specific functions (using its
embedded sensors) as well as to communicate with the patient (using customized apps). Ambient sensors and computer technologies are used in
the home settings to gather additional information or replace wearable sensors when wearable sensors cannot be used. The integration of wearable
technology with smart devices enables the remote monitoring of patients with PD and real-time feedback to clinicians, family/caregivers, and the
patients themselves. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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measured represents a therapeutic target and hence the
measurement must be relevant to the treatment ques-
tion (Table 1).
The Case for Multidomain, Multisensor,
Integrated Technology
PD is characterized by considerable inter- and intra-
subject clinical variability in clinical symptoms. What
matters most for one patient in the motor sphere may
not be as important for another (eg, tremor vs. freez-
ing of gait vs sleep disturbance) given the different lev-
els of functional disability.30 Fluctuations in daily
functioning in some patients may only include nonmo-
tor phenomena (eg, fatigue or anxiety).31 Even if we
were to accurately measure the most overt deficit,
most patients display a repertoire of motor and non-
motor endpoints that vary within and between days,
with varying impacts on their quality of life.32 Thus, a
multidomain, multisensor, smart technology is needed
to determine the source of all relevant changes, iden-
tify individualized disease fingerprints, and develop
truly personalized therapeutic approaches.
Challenges
The Need for Monitoring Nonmotor Symptoms
The development of wearable systems to monitor
individuals with PD has focused heavily on motor
aspects of the disease (eg, tremor, bradykinesia, gait
impairment, and dyskinesia)33-35 that are also, albeit
with lower sensitivity and specificity, evaluated by
clinical scales. Despite recent advances in the quantifi-
cation of motor symptoms such as tremor, these end-
points often bear only modest quantitative agreement
with measures of quality of life.36,37 Indeed, patient
priorities and sources of disability often arise from
nonmotor deficits (eg, depression, anxiety, fatigue,
orthostatic hypotension, sleep disturbance). Unfortu-
nately, relatively few studies have thus far focused on
capturing the fluctuations of these complex disease
manifestations, marked by high variability within and
between days.38,39 The development of TOMs for
nonmotor endpoints has relied on labor-intensive or
computerized, laboratory-based measurements (eg,
cognitive function, heart-rate variability, blood pres-
sure changes, or sleep).40,41 There is an urgent need
for developing unobtrusive systems to monitor nonmo-
tor endpoints in the home and community settings.
Limitations of Sensors Used to Monitor Motor
Symptoms
Biomechanical sensors such as accelerometers, gyro-
scopes, and magnetometers are well suited for the
detection of tremor, bradykinesia, gait impairment,
and motor complications, such as dyskinesia.
However, data collected in the home and community
settings using these sensors do not always provide suf-
ficient information to achieve a reliable clinical assess-
ment of motor symptoms. For instance, it is difficult
to infer from the sensor data alone if slowness of
movement (as detected using biomechanical sensors)
can be used as a proxy of bradykinesia or is the result
of fatigue or other factors related to the context in
which a motor task is performed (eg, slow walking
because of fear of falling). Also, the resolution of bio-
mechanical sensors is restricted to the anatomical area
on which they are applied, which may yield low quan-
titative agreement with the wider range of motor dis-
ability, quality of life, and other measurable patient-
relevant endpoints.36,37
Discrepancy Between Clinical
Needs and Research
Endpoints that may be ideally suited for a clinical
study may not necessarily be relevant or applicable in
clinical care. The relevance of specific TOMs to assess-
ing the impact of parkinsonian symptoms on a
patient’s quality of life may be difficult to evaluate.
For instance, fluctuations in motor symptoms and
complications such as dyskinesia may have a complex
quantitative relationship with measures of disability.42
In addition, the measurement target and timeline of
data capture differ depending on the goals of a study.
For example, an instrumented test that captures finger
tapping over several hours may suffice to track the
immediate response to a dopaminergic therapy. How-
ever, monitoring disease progression over time
involves more complex targets and longer data collec-
tion, such as physical activity levels, gait speed, fre-
quency of falls and near fall events, as well as a
variety of periodic or continuously gathered measures
of motor, cognitive, or other nonmotor functions. In
many cases, the accuracy and reliability of these
TOMs may not yet be sufficient to justify their deploy-
ment in phase III clinical trials.
Lack of Compatibility Among
Wearable Systems
Most wearable systems developed to monitor indi-
viduals with PD are not compatible with one another.
As a result, it may be cumbersome or impossible to
combine data gathered by TOMs developed by differ-
ent manufacturers. This makes it difficult to guide
behavioral changes or therapeutic interventions. Fur-
thermore, devices developed by different manufac-
turers for the same purpose may not always yield the
same result, raising questions about the validity of the
mathematical algorithms that govern the data process-
ing. Few currently available systems gather synchron-
ized data from multiple body segments before transfer
to a computer for whole-body analysis43 in a way that
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is fully compatible with the simultaneous use of plat-
forms developed by different manufacturers.
Limitations of Available Analytical Methods
Despite our ability to collect and store extremely
large datasets of TOMs, our ability to algorithmically
analyze and synthetically display clinically and
disease-relevant information to physicians and patients
remains limited. Here, clinical expertise is needed, for
instance, to eliminate the “clinical noise” in the data
analytical efforts. In addition, technical expertise is
needed so that the field can take advantage of the tre-
mendous advances that have been achieved during the
past 2 decades in research areas such as signal process-
ing and machine learning. Data analysis techniques
that leverage advances in these research areas are
important to achieving clinically meaningful TOMs.
Practical Limitations in User Engagement
Software and hardware components of wearable sys-
tems are often not as user friendly or compelling to
adopt as they should be.44 Currently, patient and care-
giver engagement with wearable and mobile technol-
ogy is modest, as shown by a recent study
demonstrating that 32% of users stop using wearables
after 6 months, and 50% after slightly more than a
year.45 Similarly, there is a high dropout rate among
smartphone apps users: 26% of apps are used only
once and 74% of apps are not used more than 10
times.45,46 Lack of motivation to use wearables/self-
monitoring systems should not be underestimated,
particularly in the absence of meaningful feedback
provided to their users. Preliminary evidence suggests
that patient empowerment and their inclusion as
active players in the development of research activities
may favorably impact compliance.47 Research is
needed to determine the characteristics of wearable
systems for long-term monitoring of motor and non-
motor symptoms that would be acceptable to patients.
In particular, we need to ascertain the number of sen-
sors needed to accurately monitor PD symptoms with-
out negatively affecting compliance in a clinical
context.
Opportunities
Wearable systems provide the opportunity to mea-
sure and monitor the individual variability of motor
and nonmotor phenomena, minimize rater bias, and
increase sensitivity to subclinical but possibly relevant
physiologic changes (Table 2).4,10,48,49
Standard Measurement Platform
Several companies have tested or are in the process
of assessing a variety of methods to probe individual
motor and nonmotor constructs. To avoid duplication
of investments and efforts, an opportunity exists to
identify the technologies and approaches with most
versatility, greatest ease of deployment, least patient
and physician encumbrance, and lowest cost. It should
no longer be a question of whether a given motor phe-
nomenon can be measured in yet a different manner
(which it can), but how to choose a standard platform
of TOMs behind which developers and end-users can
coalesce. Efforts toward standardization—guided by
the Movement Disorders Society Task Force on
TABLE 2. Limitations of existing technology-based objective measures (TOMs) and opportunities for the development of
new TOMs using wearable technology
Limitations Main roadblocks Opportunities
Limited measurement Low spatial resolution
Single sensor data capture
Multiple sensors
Recording multiple motor and nonmotor behaviors
Measure their natural variability
Open-loop data capture Failure to connect to other sensors or inform treatment Continuous feedback into a closed-loop system
that dictate treatment changes
High burden-to-value ratio The larger the number of sensors used, the more
significant is the negative impact on activities
and adherence
Minimally obtrusive, continuously sensing systems
Improve compliance
Less missing data
Lower cost of care
Noninteractivity Off-line and unidirectional (ie, clinician to patient)
feedback modalities are not effective
Increasing real-time interaction between patient and data
and between patient and clinician
Decrease need for in-person clinical visits
Personalize and improve patient care
Multiplicity of technology
platforms
Too many incompatible devices
Duplicative efforts
Poor comparability of measures
Limited interoperability
Standardization of platform
Increasing TOM sensitivitya
Increasing TOM reliability
Decreasing measurement errors
More contextual information
aHowever, small changes of particularly sensitive measures may not necessarily be clinically relevant (eg, levodopa-induced, peak-dose dyskinesia could vary
in amplitude but not bear a significant impact on disability because of the nonlinear relationship between amplitude of dyskinetic movements and disability).
E S P A Y E T A L
6 Movement Disorders, Vol. 00, No. 00, 2016
Technology but endorsed or sanctioned by regulatory
agencies such as the Food and Drug Administration
(FDA) and the European Medicines Agency (EMA)—
will greatly facilitate technology adoption and the
integration of different systems.
Multidomain Measurements
With different types of disabilities comes the need
for tailored measurement approaches to support the
design of individualized interventions. Tremor mea-
surement may be completely irrelevant to individuals
with an akinetic or postural-instability gait-disorder
phenotype of PD. Continuous step monitoring to cap-
ture freezing of gait episodes would be futile in
patients without gait impairment. Systems that are
designed for multidomain data capture could provide
researchers and clinicians with the flexibility of choos-
ing the sensors to monitor individuals with different
phenotypes of PD. In exploratory studies, an approach
based on multidomain data capture would increase
the likelihood of finding relevant changes in one of the
many channels of the system. This approach would
also provide the opportunity for assessing correlated
effects of symptoms of interest across other domains.
Better Phenotyping and Subtyping
Tremor and tremorless (akinetic/postural-instability
gait-disorder) variants of PD are grossly defined clini-
cal phenotypes based on mainly observational evi-
dence, with substantial heterogeneity.50 Besides these
clinical phenotypes, there likely exist several disease
subtypes defined by autonomic, cognitive, or other
domains of disability that could be captured by multi-
channel systems.51 In addition, it is conceivable that
the greater resolution of TOMS may detect novel phe-
nomena that could serve to more sensitively stratify
certain PD subtypes and serve as (or assist in the
development of) biomarkers of disease progression.
Precision Medicine
By identifying areas of dysfunction and their rela-
tionship with therapy, TOMs can be used to provide
customized feedback to individual patients and possi-
bly stratify criteria that predict the responsiveness to
distinct treatment paradigms in a way that is similar
to how consumer-based wearable devices already mea-
sure level of activity, sleep disturbances, and so on.
Smart algorithms could be developed to generate spe-
cific recommendations that would be made available
directly to patients and clinicians to motivate changes
in treatment and lifestyle-related behaviors, tailored to
each person’s specific individual needs and disabilities.
This approach would provide value for end-users
(both patients and their care team) and thereby
improve adherence.
Closed-Loop (Feedback) Systems
Data collected using wearable sensors could be used
to trigger device-based interventions. Much as electro-
cardiography sensing is used in cardiac defibrillators to
trigger the delivery of stimulation pulses, data collected
from sensors positioned on the limbs and trunk could
be used to predict, for instance, the onset of a freezing
episode. The system may detect an increase in cadence
with a corresponding decrease in step length or a change
in frequency of the lower leg oscillations.34 The detec-
tion of such motor behaviors could trigger a device
designed to deliver proprioceptive cues that could lead
to a change in postural control and stepping pattern,
which in turn could prevent a fall.43,52,53
Real-Time Symptom Tracking
TOMs could offer real-time, continuously captured,
rater-independent data in contrast with clinical assess-
ments that rely on subjective information gathered
during sporadic, in-clinic evaluations.54 Continuous
monitoring of parkinsonian symptoms could replace
diary-based recordings of fluctuations and be used to
track periods of OFF, OFF with dystonia or dyskinesia
(not currently captured using the Hauser diary), ON, and
ON with dyskinesia over the time span of several days.
The Promise of Remote Monitoring
TOMs based on the use of wearable systems could
improve healthcare delivery by providing assessment
data when patients are not in the clinic. This possibility
is particularly relevant for individuals with PD who live
in areas with limited access to care. TOMs could pro-
vide ecologically valid data to help clinicians monitor
responses to therapy and individualize management to
optimize outcomes.49 Remote monitoring also offers
the opportunity for healthcare cost reduction.8
Better Monitoring, Better Patient Engagement,
Better Outcomes
Innovation in sensor and communication technologies
alongside mobile connectivity has enabled a process of
medical democratization.1 The creation or support of
TOMs for remote, continuous monitoring provides an
opportunity for healthcare providers to scale and extend
services offered to patients to better manage their health.55
TOMs can capture meaningful aspects of function that
improve personalized patient care through an intuitive,
interconnected, and energy-efficient interface.56,57
Potential Pitfalls in Developing
TOMs
Clinimetric Validation Pitfall
A number of studies have focused on developing
methods to derive TOMs that parallel the clinical
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assessment scales commonly used in clinics. These are
important but potentially misguided efforts toward
validating new TOMs in the clinic or home settings by
attempting to force a simple quantitative agreement
with widely used, previously validated subjective rat-
ing scales or questionnaires. However, it could be
argued that, in theory, a “perfect” objective measure-
ment should have a complicated quantitative match
with an “imperfect” subjective one. This is because a
clinical rater integrates many sources of information
to produce a subjective score, including prior experi-
ence and expectations. So there is no a priori reason
to believe that assessments performed by clinical raters
would lead to a simple quantitative agreement with
data features derived from sensor data. Indeed, the
relationship between TOMs and subjective clinical
scores may be highly complex and extremely difficult
to ascertain in practice.
To the extent that we are seeking more sensitive and
ecologically valid technologies, TOMs may agree only
loosely with clinical scales. An important aim of
TOMs is to improve on, rather than act as surrogates
of, previously developed clinical scales. As these are
developed, clinicians and regulatory agencies will need
to consider that a new TOM that appears to provide
clinically relevant measures of movement characteris-
tics, but which does not correlate with the motor sec-
tion of the Unified Parkinson Disease Rating Scale, for
example, could be accepted as valid on the basis of its
own merits if it can accurately represent patient-
relevant endpoints. Engineers and clinicians alike
should be reminded to think outside the box and use
the power of the technology to develop new scoring
paradigms rather than solely generate sensor-based
versions of existing clinical scores.
Ecological Validity Pitfall
Efforts in ensuring validity, or the degree to which
we are truly measuring what we intend to measure,
increase in complexity with proliferating technologies,
evolving in different platforms and on different targets
with unclear ecological and clinical relevance. To this
end, before developing new TOMs, researchers would
need to determine which constructs generated by rou-
tine clinical observations, and standardized by clinical
scales and medical devices, are truly relevant to
patients within such domains and are meaningful con-
tributors to the performance of activities of daily liv-
ing. For example, if “dyskinesia” is not relevant as a
construct to patients and is not a significant contribu-
tor to the performance of activities of daily living in
their ecological environment, do we invest in main-
taining its primacy in future technologies? Efforts to
ensure system interoperability and to build open data
repositories will help distinguish relevant from futile
TOMs.
“Big Data” Pitfall
It has been demonstrated that an abundance of
behavioral data can be captured from individuals and
populations using largely unstructured, crowd-sourced
efforts. These data may differentiate populations of
loosely defined PD (on the basis of generic measures
of movement abnormalities) from healthy individuals.
However, although these measures can provide valua-
ble background information at the population and
community levels, they cannot substitute for a careful
neurological examination, deep clinical phenotyping,
and assessment via laboratory studies. At best, they
complement but do not replace the phenomenological
and pathophysiological granularity required for PD
subtyping, much less predict the response of an indi-
vidual to treatment. Ultimately, the reproducibility
and responsiveness of individually selected TOMs con-
firmed beyond small pilot studies and accounting for
contextual information and confounders, should pre-
vail over simply obtaining a large body of population-
level data.
Preparing for TOMs in Clinical Care
and the Research Setting
Wearable systems that are used to gather TOMs in
the home and community settings could generate real-
time, accurate, sensitive, and rich datasets including
contextual information and data such as the time of
medication, food intake, and location information.
Although TOMs are typically derived from wearable
sensors, contextual information is captured using com-
panion applications (eg, mobile apps and web-based
applications). Wearable systems that are used to
gather TOMs also provide an opportunity for multi-
directional interactions among investigators/clinicians
and patients/caregivers at a reasonable cost. In the
clinical care setting, the use of wearable systems to
generate TOMs could decrease the need for outpatient
visits while maintaining high-quality care and high
patient engagement. Likewise, the integration of
TOMs with virtual-visit interfaces has the potential to
greatly improve the accuracy and value of telemedi-
cine visits. In the clinical research setting, the use of
wearable systems could enhance protocol adherence
and patient compliance, leading to fewer missing data
points. Also, an appropriate choice of TOMs could
lead to prospectively collecting data with a high
signal-to-noise ratio (with regard to the effect size of
interest) hence reducing the required sample size and
the resulting study costs. The composite of TOMs,
companion applications designed to gather contextual
information and pharmacogenomics could enable pre-
cision medicine interventions.58
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Integrating Technologies
The development of new TOMs is currently advanc-
ing in isolated silos rather than as part of concerted
actions aimed to implement open platforms. The
development of open platforms would be highly desir-
able in the context of obtaining comprehensive infor-
mation on patients and populations of interest. An
open platform may not yet be fostered by the brave
new world of health-driven technologies. However,
there are reasons for optimism. Although in the tradi-
tional medical device market, short-term financial
forces drive the creation of proprietary measuring
instruments at the expense of multichannel, intercon-
nected systems, consumer-driven market forces are
pushing heavily in the opposite direction, that is,
toward the development of open technology plat-
forms. As consumer technologies evolve to achieve the
clinimetric sophistication required for application in
the clinical management of individuals with PD, the
move toward shared, interoperable software and hard-
ware for applications in research and clinical practice
is also emerging.
Smart Delivery of Treatment
Justification for the development and adoption of
TOMs is strongest when presented in the context of
improving the clinical management of individuals with
PD. TOMs can be used as part of closed-loop systems
designed to assist in the controlled delivery of medica-
tions. The development of such systems requires man-
ufacturing high-performance, energy-efficient, and
energy-harvesting sensors and storage modules.59 In
this context, the development of nanomembranes and
stretchable electronics on a polymeric substrate for
intimate mechanical contact with soft tissue has been
proposed.60 A critical unmet need is the ability to con-
nect multisensor diagnostics to self-guided therapies in
a closed-loop system. In the field of neuromodulation,
deep brain stimulation (DBS) electrodes may also act
as sensors capable of recording local field potentials
(for the presence or absence of beta-band oscillations)
to automatically program the amplitude and frequency
of stimulation, thus effectively closing the loop
between measuring and treating.61
Objective measures of specific movement impair-
ments can also be used to tailor therapy. Proof of con-
cept systems have been developed to predict the onset
of pathological tremor using surface electromyo-
graphic and acceleration data, which could inform the
design of the next generation of noninvasive closed-
loop predictive ON-OFF controllers for DBS.62,63 In
the realm of physical rehabilitation, subtle asymme-
tries in gait, limitations in joint range of motion, or
excessive postural sway indicating poor balance may
be difficult to observe clinically but can be addressed
by rehabilitation specialists when identified using
TOMs. Through TOMs, therapists could personalize
the therapy prescribed to each individual.43 A simple
clinical measure such as the time needed to walk a
specified distance does not provide the therapist with
an understanding of the spatial and temporal gait per-
formance or the musculoskeletal and dynamic balance
characteristics that cause poor mobility. These factors
could be captured using TOMs and hence guide the
choice of appropriate therapeutic approaches. Longitu-
dinal monitoring of TOMs also has the potential for
identifying small improvements or declines related to
the intervention or the progression of the disease that
could lead to changes in the prescribed rehabilitation
intervention.
Regulatory Needs and Commercialization
We anticipate that TOMs will eventually be rou-
tinely used in both clinical practice and research set-
tings. Despite the promise of greater sensitivity and
the presumed accuracy of collected data, regulatory
validation of TOMs as efficacy and safety measures
will require dedicated studies. The path to marketing
for TOMs appears long and risky considering the
short lifecycle of technological innovation and the
costs associated with their development. Unlike drug
development, where there is substantial precedent and
a regimented path for marketing authorization, com-
mercialization, and license protection, the path for
TOMs and digital health solutions remains to be
defined. It is critical that key stakeholders share the
costs and financial rewards of technology develop-
ment, implementation, and maintenance to accelerate
and preserve innovation and growth. Despite opportu-
nities to meet all stakeholder needs, the business
model for development and deployment of TOMs in
healthcare remains to be determined. Currently,
healthcare payers show little incentive to financially
reimburse TOMs despite the promise for healthcare
cost reduction, population management, and delivery
of high-quality, efficient care. The lack of incentive
may be driven by initial expenditures and the com-
plexity of a rapidly evolving, but not yet fully inte-
grated, technology market. Providers are also reluctant
to fully adopt TOMs despite early evidence that they
can improve patient outcomes and lead to overall
improved care and patient satisfaction. Clinicians may
not yet view TOMs as an opportunity to support clini-
cal decision making and increase productivity. Patients
are also reluctant to pay out of pocket despite oppor-
tunities for improved access to better care and better
outcomes. Building a solid business case—including
properly designed cost-effectiveness studies—is much
needed. A value-based care approach could be an
attractive solution in which deployment of TOMs is
funded as part of an integrated care solution where
providers are rewarded for good outcomes per
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invested dollar and in which the decision to engage
TOMs is left to the providers and patients. Finally, in
addition to funding agencies, regulatory bodies such
as the FDA and the EMA should increase efforts
toward establishing programs that encourage the
adoption of standards aimed to assure interoperability
of wearable systems and the development of open
data repositories.
Integration Into Medical Care and
Reimbursement
Payers do not yet provide reimbursement for medi-
cal services provided by TOMs and companion apps.
This limits the rate of innovation and the opportuni-
ties for integration of TOMs into medical care. Estab-
lishing reimbursement mechanisms will require
demonstration that, along with the enhancements in
diagnostics and therapeutics, TOMs can be integrated
in quality-control concepts, help reduce costs and
time, and improve the quality of life for patients while
guarding against privacy concerns. Quantifying clini-
cal benefits of interventions using TOMs is anticipated
to become increasingly important in healthcare as the
allocation of resources is expected to be tied to objec-
tive outcome measures.
Conclusions and Next Steps
Despite challenges, the continuous improvements in
technological sophistication, versatility, and wearabil-
ity of sensors have created opportunities to collect
disease-relevant data using targets consequential to
patients and sensitive to PD-specific symptoms and
milestones. To translate these opportunities into
enhanced care, better self-management options for PD
patients, and overall improved healthcare outcomes,
technologies will need to be (1) developed as open
platforms and integrated with electronic medical
record systems, (2) suitable for the acquisition of data
that captures motor and nonmotor phenomena, and
(3) integrated in treatment delivery systems. The Inter-
national Parkinson and Movement Disorders Society
Task Force on Technology aims at reversing the cur-
rent model of simply adapting available technologies
to meet patient management and research endpoints.
As such, the task force will assist in improving the
academic and regulatory environments for technology
developers by encouraging the sanctioning of open
standard platforms for technology-based measure-
ments and treatments by, for example, the FDA and
EMA. This collaborative endeavor will encourage the
development of integrated, multichannel, and in many
instances closed-loop feedback systems that can
achieve more sophisticated clinico-pathophysiologic
characterization, better informed tailoring of sympto-
matic therapy, greater patient engagement and self-
assessment, and better subgroup targeting of patients
for testing of future disease-modifying treatments.
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